Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours By Ogkologos - February 10, 2026 170 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRIDENT-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows December 13, 2018 Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells October 15, 2019 New drug combo for advanced breast cancer approved for NHS in... August 12, 2021 ETV6 Protein Could Be an Important Target for Ewing Sarcoma Treatment March 7, 2023 Load more HOT NEWS Courageous children receive Star Awards in virtual celebration ESMO Targeted Anticancer Therapies Congress 2024, 26-28 February, Paris, France New on NCI’s Websites for June 2023 Por qué la Reunión Anual de la American Society of Clinical...
